# XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study

> **NCT01249027** · — · COMPLETED · sponsor: **Abbott Medical Devices** · enrollment: 2605 (actual)

## Conditions studied

- Angioplasty
- Chronic Coronary Occlusion
- Stent Thrombosis
- Vascular Disease
- Myocardial Ischemia
- Coronary Artery Stenosis
- Coronary Disease
- Coronary Artery Disease
- Coronary Restenosis

## Interventions

- **DEVICE:** XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

## Key facts

- **NCT ID:** NCT01249027
- **Lead sponsor:** Abbott Medical Devices
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2016-12
- **Final completion:** 2017-01
- **Target enrollment:** 2605 (ACTUAL)
- **Last updated:** 2019-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01249027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01249027, "XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01249027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*